Additional file 1: of Chronic low back pain patients’ use of, level of knowledge of and perceived benefits of complementary medicine: a cross-sectional study at an academic pain center

Study questionnaire (in French). (DOCX 67 kb

Impact of EVD on referral sensitivity.

<p><b>(A)</b> Mean referral time (days since symptom onset at triage) for EVD(+) and EVD(-) cohorts. <b>(B)</b> Fitted relationship between referral time and outcome using fractional polynomial analysis [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005356#pntd.0005356.ref025" target="_blank">25</a>]. <b>(C)</b> Mean referral time for EVD(+) and EVD(-) patients according to age categorisation. <b>(D)</b> Mean referral time for EVD(-) and EVD(+) patients over the entire time course of the study (December 2014 to October 2015). *: p<0.05, **: p<0.005, ***: p<0.001, ns: not significant, ETC: Ebola Treatment Centre.</p

Baseline characteristics of participants.

<p>Baseline characteristics of participants.</p

Regression model for number of drinks per week, baseline to 6 months (n = 896).

<p>Regression model for number of drinks per week, baseline to 6 months (n = 896).</p

Study participant flow and follow-up rates.

<p>Study participant flow and follow-up rates.</p

Epidemiological characteristics of EVD outcome.

<p><b>(A)</b> Kaplan-Meier survival analysis of patients in the ETC according to their EVD status. <b>(B)</b> Mortality among EVD(-) and EVD(+) admissions according to gender. <b>(C)</b> Average age of death among EVD(-) and EVD(+) patients. <b>(D)</b> Mortality rate across age groups in EVD(-) and EVD(+) cohorts. Dotted lines represent the average mortality rate across all ages in the cohort. Statistics in <b>(C)</b> calculated by unpaired t test *: p<0.05, **: p<0.005, ***: p<0.001, ns: not significant.</p

Accuracy of current triage methods.

<p><b>(A)</b> Number of EVD(+) and EVD(-) patients triaged into the low-risk “suspect” and high-risk “probable” wards using the WHO triage protocol [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005356#pntd.0005356.ref007" target="_blank">7</a>]. <b>(B)</b> Number of days spent in the ETC according to the probability of being diagnosed as either EVD(+) (red) or EVD(-) with malaria (green) or with neither EVD nor malaria (blue). <b>(C)</b> The sensitivity and specificity of predicting EVD(+) patients in our cohort using the scoring system of Levine et al. [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005356#pntd.0005356.ref011" target="_blank">11</a>]. The area under the receiver-operator characteristic (ROC) curve represents the discriminative power of the score. <b>(D)</b> Percentage of EVD(+) and EVD(-) patients in our cohort classified in the various risk categories as proposed by the scoring system of Levine et al. [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005356#pntd.0005356.ref011" target="_blank">11</a>].</p

Prognostic value of Ebola virus load (Ct value).

<p><b>(A)</b> Distribution of Ct values¹ for EVD(+) patients considered to have a high viral load (Ct ≤ 20) and low viral load (Ct > 20). <b>(B)</b> Ct value distribution across age in the EVD(+) cohort. The red line plots the fractional polynomial prediction of the Ct value. <b>(C)</b> Ct values amongst survivors and fatalities in the EVD(+) cohort. <b>(D)</b> Kaplan-Meier survival analysis of EVD(+) patients according their Ebola virus loads, either considered as high viral (Ct ≤ 20) or low viral load (Ct > 20). ¹ Ct values represent Ebola-specific qRT-PCR results (inversely proportional to the viral load). Statistics in <b>(C)</b> calculated by unpaired t test *: p<0.05, **: p<0.005, ***: p<0.001, ns: not significant.</p

Scorecard to extrapolate the Ebola infection risk at triage.

<p>Scorecard to extrapolate the Ebola infection risk at triage.</p

Prevalence of the clinical signs and symptoms recorded at triage.

<p><b>(A)</b> Prevalence of triage symptoms for EVD(+) and EVD(-) cohorts ranked according to the prevalence in EVD(+). Rankings from 1–16 are listed above each bar: black for EVD(+) and grey for EVD(-). <b>(B)</b> Differences in symptom prevalence between EVD(+) and EVD(-) cohorts. Positive values are more prevalent in EVD(+) cases. Negative values are more prevalent in EVD(-) cases. <b>(C)</b> Differences in symptom prevalence between EVD(+)only patients and malaria(+)only patients. Positive values are more prevalent in EVD(+)only cases. Negative values are more prevalent in malaria(+)only cases. <b>EVD(+)only:</b> EVD(+)/malaria(-); <b>Malaria(+)only:</b> EVD(-)/malaria(+)</p